Search
Asthma Clinical Trials in Dearborn, MI
A listing of 2 Asthma clinical trials in Dearborn, MI actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 2 of 2
The city of Dearborn, Michigan, currently has 2 active clinical trials seeking participants for Asthma research studies.
Featured Trial
Clinical Studies for COPD
Recruiting
Clinical Studies for COPD
Conditions:
COPD
Copd Exacerbation Acute
Emphysema or COPD
COPD Asthma
Chronic Obstructive Pulmonary Disease(COPD)
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Asthma Clinical Trials
Recruiting
Enroll in a clinical trial now and move closer to discovering an improved solution tailored for you. Receive compensation for your participation, along with free medical treatment.
Conditions:
Asthma
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype
Recruiting
This study will assess whether switching participants who have benefitted from mepolizumab or benralizumab to GSK3511294 (Depemokimab) is non-inferior to maintaining current treatment on the annualized rate of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all participants will continue their non-biologic Baseline standard of care (SoC) asthma treatment.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/29/2024
Locations: GSK Investigational Site, Dearborn, Michigan
Conditions: Asthma
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
Recruiting
This is an interventional, randomized, parallel group, treatment, Phase 3b/4, double blind, 2-arm study to assess the effect of dupilumab compared to standard of care therapy on preventing or slowing the rate of lung function decline in adult patients with uncontrolled moderate to severe asthma.
The estimated duration is 4±1 weeks of screening and run-in period, followed by a 3-year double blinded treatment period. There will be a post-treatment follow-up (FU) period up to 12 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Revival Research Institute, LLC Site Number : 8400097, Dearborn, Michigan
Conditions: Asthma
1 - 2 of 2